Abstract
AbstractBackgroundNeuroinflammation is considered one of major factors in the pathogenesis of Alzheimer’s disease (AD). In particular, inflammasome activation, including NLRP3 inflammasome in microglia, is regarded as fundamental for the pro‐inflammatory response of immune cells (Hanslik & Ulland, 2020). Aβ functions to primarily activate microglia in AD and reports have been made that Aβ can activate NLRP3 inflammasome(Halle et al., 2008). However, the precise molecular mechanism through which the NLRP3 inflammasome is associated with AD pathologies remains unclear.MethodPrimary microglia were treated with LPS and Aβ, and the induced signaling pathway were examined by RT‐PCR, western blot and immunostaining. Effect of flufenamic acid (FA) were examined and various inhibitors of Syk, AMPK and NLRP3 were used for the verification of the hypothesis. AD mouse model expressing Aβ and tau pathology were intraperitoneally treated with FA. After behavior tests, their brains were obtained for western blot and immunostaining.ResultAβ activates the NLRP3 inflammasome in microglia by activating Syk and inhibiting AMPK. Deactivated AMPK induces metabolic dysregulation, mitochondrial fragmentation and reactive oxygen species formation, leading to the activation of the NLRP3 inflammasome. In addition, flufenamic acid (FA), a member of non‐steroid anti‐inflammatory drugs, was found to effectively inhibit activation of the microglial NLRP3 inflammasome by regulating Syk and AMPK. Importantly, FA has marked therapeutic effects on major AD pathologies including amyloid plaque formation, tau phosphorylation, gliosis and memory dysfunction in vivo in microglia‐dependent way.ConclusionThe molecular mechanism of microglial NLRP3 inflammasome activation by Aβ was demonstrated to be Syk‐AMPK pathway. Also, FA can be repurposed for inhibiting microglial activation of the NLRP3 inflammasome, which is a potential treatment for AD.*ReferencesHanslik, K. L., & Ulland, T. K. (2020). The Role of Microglia and the Nlrp3 Inflammasome in Alzheimer’s Disease. Frontiers in Neurology, 11.Halle, A., Hornung, V., Petzold, G. C., Stewart, C. R., Monks, B. G., Reinheckel, T., Fitzgerald, K. A., Latz, E., Moore, K. J., & Golenbock, D. T. (2008). The NALP3 inflammasome is involved in the innate immune response to amyloid‐β. Nature immunology, 9(8), 857.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.